VistaGen Therapeutics Ownership
| VTGN Stock | USD 2.79 0.02 0.72% |
Shares in Circulation | First Issued 2011-09-30 | Previous Quarter 31 M | Current Value 31 M | Avarage Shares Outstanding 7 M | Quarterly Volatility 9.5 M |
VistaGen |
VistaGen Stock Ownership Analysis
About 53.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.99. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 1.48. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system . VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Vistagen Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. For more information please call Shawn JD at 650 577 3600 or visit https://www.vistagen.com.Besides selling stocks to institutional investors, VistaGen Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different VistaGen Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align VistaGen Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
VistaGen Therapeutics Quarterly Liabilities And Stockholders Equity |
|
VistaGen Therapeutics Insider Trades History
Less than 1% of VistaGen Therapeutics are currently held by insiders. Unlike VistaGen Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against VistaGen Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of VistaGen Therapeutics' insider trades
VistaGen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VistaGen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading VistaGen Therapeutics backward and forwards among themselves. VistaGen Therapeutics' institutional investor refers to the entity that pools money to purchase VistaGen Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 194.5 K | Bml Capital Management Llc | 2024-12-31 | 150 K | Two Sigma Investments Llc | 2024-12-31 | 137.3 K | Ubs Group Ag | 2024-12-31 | 132.3 K | Persistent Asset Partners Limited | 2024-12-31 | 121.7 K | Adar1 Capital Management Llc | 2024-12-31 | 121.5 K | Squarepoint Ops Llc | 2024-12-31 | 107.7 K | Advisorshares Investments, Llc | 2024-12-31 | 99.8 K | Blair William & Co | 2024-12-31 | 98.5 K | Tcg Crossover Management, Llc | 2024-12-31 | 2.7 M | Stempoint Capital Lp | 2024-12-31 | 2.3 M |
VistaGen Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VistaGen Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VistaGen Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VistaGen Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VistaGen Therapeutics Outstanding Bonds
VistaGen Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. VistaGen Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VistaGen bonds can be classified according to their maturity, which is the date when VistaGen Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US92840JAB52 Corp BondUS92840JAB52 | View | |
| VSTJET 7875 01 MAY 27 Corp BondUS92840JAD19 | View | |
| VST 5125 13 MAY 25 Corp BondUS92840VAL62 | View | |
| US92840VAH50 Corp BondUS92840VAH50 | View | |
| VISTRA OPERATIONS LLC Corp BondUS92840VAG77 | View | |
| Vistra Operations Co Corp BondUS92840VAF94 | View | |
| Vistra Operations Co Corp BondUS92840VAE20 | View |
VistaGen Therapeutics Corporate Filings
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against VistaGen Stock
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.